|
1
|
Alphavbeta3 and alphavbeta5 integrins control glioma cell response to ionising radiation through ILK and RhoB.
|
Int J Cancer
|
2008
|
1.22
|
|
2
|
Alphavbeta3/alphavbeta5 integrins-FAK-RhoB: a novel pathway for hypoxia regulation in glioblastoma.
|
Cancer Res
|
2009
|
1.20
|
|
3
|
Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.
|
Cancer Epidemiol Biomarkers Prev
|
2010
|
1.01
|
|
4
|
Activation of RhoB by hypoxia controls hypoxia-inducible factor-1alpha stabilization through glycogen synthase kinase-3 in U87 glioblastoma cells.
|
Cancer Res
|
2006
|
0.99
|
|
5
|
Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation.
|
Int J Cancer
|
2002
|
0.93
|
|
6
|
Breast cancer risk in BRCA1 and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 gene.
|
Int J Cancer
|
2005
|
0.91
|
|
7
|
The farnesyltransferase inhibitor R115777 reduces hypoxia and matrix metalloproteinase 2 expression in human glioma xenograft.
|
Clin Cancer Res
|
2003
|
0.87
|
|
8
|
Inhibition of Rho pathways induces radiosensitization and oxygenation in human glioblastoma xenografts.
|
Oncogene
|
2003
|
0.86
|
|
9
|
Increased expression of a COOH-truncated nucleophosmin resulting from alternative splicing is associated with cellular resistance to ionizing radiation in HeLa cells.
|
Int J Cancer
|
2002
|
0.86
|
|
10
|
Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers.
|
Cancer Epidemiol Biomarkers Prev
|
2005
|
0.86
|
|
11
|
The c.5242C>A BRCA1 missense variant induces exon skipping by increasing splicing repressors binding.
|
Breast Cancer Res Treat
|
2009
|
0.85
|
|
12
|
The radioprotective effect of the 24 kDa FGF-2 isoform in HeLa cells is related to an increased expression and activity of the DNA dependent protein kinase (DNA-PK) catalytic subunit.
|
Oncogene
|
2002
|
0.85
|
|
13
|
Phase I trial of tipifarnib (R115777) concurrent with radiotherapy in patients with glioblastoma multiforme.
|
Int J Radiat Oncol Biol Phys
|
2007
|
0.84
|
|
14
|
Two prognostic groups of inflammatory breast cancer have distinct genotypes.
|
Clin Cancer Res
|
2003
|
0.84
|
|
15
|
Radiation-induced mitotic cell death and glioblastoma radioresistance: a new regulating pathway controlled by integrin-linked kinase, hypoxia-inducible factor 1 alpha and survivin in U87 cells.
|
Eur J Cancer
|
2013
|
0.81
|
|
16
|
Simplified identification of Lynch syndrome: a prospective, multicenter study.
|
Dig Liver Dis
|
2012
|
0.81
|
|
17
|
Basic fibroblast growth factor-2/beta3 integrin expression profile: signature of local progression after chemoradiotherapy for patients with locally advanced non-small-cell lung cancer.
|
Int J Radiat Oncol Biol Phys
|
2009
|
0.80
|
|
18
|
RhoB controls the 24 kDa FGF-2-induced radioresistance in HeLa cells by preventing post-mitotic cell death.
|
Oncogene
|
2002
|
0.79
|
|
19
|
BRCA1 wild-type allele modifies risk of ovarian cancer in carriers of BRCA1 germ-line mutations.
|
Cancer Epidemiol Biomarkers Prev
|
2003
|
0.79
|
|
20
|
The prognostic significance of lymphovascular invasion on biopsy specimens in lung cancer treated with definitive chemoradiotherapy.
|
Clin Lung Cancer
|
2012
|
0.78
|
|
21
|
Decreased efficiency of MSH6 mRNA polyadenylation linked to a 20-base-pair duplication in Lynch syndrome families.
|
Cell Cycle
|
2012
|
0.77
|
|
22
|
A novel germline CHEK2 deletion truncating the kinase domain identified in a French family with high-risk of breast/ovarian cancer.
|
Breast Cancer Res Treat
|
2009
|
0.75
|